Julie Le Naour

10PUBLICATIONS
47CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biologyMicrobial geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 06, 2023
Trial watch: Toll-like receptor ligands in cancer therapy.

Julie Le Naour, Guido Kroemer

|Apr 28, 2022
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Julie Le Naour, Zsofia Sztupinszki, Vincent Carbonnier

|Oct 22, 2021
Trial watch: intratumoral immunotherapy.

Juliette Humeau, Julie Le Naour, Lorenzo Galluzzi

|Sep 08, 2021
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma.

Juliette Paillet, Céleste Plantureux, Sarah Lévesque

|Dec 21, 2020
No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19.

Adriana Petrazzuolo, Julie Le Naour, Erika Vacchelli

|Oct 13, 2020
A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency.

Julie Le Naour, Peng Liu, Liwei Zhao

Pageof 2

Frequent Collaborators

8 joint publications

Guido Kroemer

7 joint publications

Erika Vacchelli

4 joint publications

Lorenzo Galluzzi

3 joint publications

Laurence Zitvogel